On October 22, 2026 Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, reported financial results for the third quarter ended September 30, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We delivered revenue growth of 10% and adjusted EPS growth of over 15% on continued strength across our physician, hospital and consumer channels, complemented by productivity gains from automation and AI," said Jim Davis, Chairman, CEO and President. "Our robust organic revenue growth demonstrates that our solutions are fulfilling the expanding clinical care needs of an aging population as well as the increasing number of people focused on prevention and wellness. With these growth trends and our strong performance, we are raising our revenue and EPS guidance for the full year."

Recent Highlights:

Announced the ability for iPhone and iPad users in the United States to conveniently purchase a tailored Quest laboratory test panel with over 50 biomarkers directly through the Apple Health app, available to the public later this year.
Finalized a definitive agreement to acquire select outreach lab assets from a leading health system and long-time Co-Lab Solutions customer in the Northeastern U.S. Continued to advance our Co-Lab Solutions implementation and joint venture lab with Corewell Health in Michigan.
Extended our AD-Detect menu to include the FDA-cleared Roche Elecsys Phospho-Tau (217P) Plasma (pTau217) blood test and launched a new AD-Detect test panel with pTau217, amyloid beta and APOE to help guide diagnosis and treatment decisions for Alzheimer’s disease.
Advanced Project Nova from the design phase to the solutions-build phase and continue to expect to deploy Epic solutions in our first lab in the fall of 2027.
The company will hold its 2027 Investor Day on March 25, 2027, at the New York Stock Exchange. Additional information will be provided closer to the event.

Three Months Ended September 30,

Nine Months Ended September 30,

2026

2025

Change

2026

2025

Change

(dollars in millions, except per share data)

Reported:

Net revenues

$ 3,097

$ 2,816

10.0 %

$ 9,035

$ 8,229

9.8 %

Diagnostic Information Services revenues

$ 3,035

$ 2,755

10.2 %

$ 8,845

$ 8,043

10.0 %

Revenue per requisition

(4.2) %

(2.8) %

Requisition volume

14.5 %

12.9 %

Organic requisition volume

14.4 %

12.8 %

Operating income (a)

$ 479

$ 386

24.2 %

$ 1,337

$ 1,170

14.3 %

Operating income as a percentage of net revenues (a)

15.5 %

13.7 %

1.8 %

14.8 %

14.2 %

0.6 %

Net income attributable to Quest Diagnostics (a)

$ 312

$ 245

27.6 %

$ 884

$ 747

18.4 %

Diluted EPS (a)

$ 2.78

$ 2.16

28.7 %

$ 7.86

$ 6.57

19.6 %

Cash provided by operations

$ 611

$ 563

8.8 %

$ 1,486

$ 1,421

4.6 %

Capital expenditures

$ 166

$ 144

15.0 %

$ 418

$ 369

13.2 %

Adjusted (a):

Operating income

$ 517

$ 458

13.0 %

$ 1,466

$ 1,330

10.3 %

Operating income as a percentage of net revenues

16.7 %

16.3 %

0.4 %

16.2 %

16.2 %

— %

Net income attributable to Quest Diagnostics

$ 338

$ 296

14.2 %

$ 969

$ 845

14.7 %

Diluted EPS

$ 3.00

$ 2.60

15.4 %

$ 8.62

$ 7.43

16.0 %

(a)

For further details impacting the year-over-year comparisons related to operating income, operating income as a percentage of net revenues, net income attributable to Quest Diagnostics, and diluted EPS, see note 2 of the financial tables attached below.

Updated Guidance for Full Year 2026

The company updates its full year 2026 guidance as follows:

Updated Guidance

Prior Guidance

Low

High

Low

High

Net revenues

$12.065 billion

$12.105 billion

$11.95 billion

$12.05 billion

Net revenues increase

9.3 %

9.7 %

8.3 %

9.2 %

Reported diluted EPS

$10.21

$10.31

$9.97

$10.17

Adjusted diluted EPS

$11.25

$11.35

$11.05

$11.25

Cash provided by operations

Approximately $1.90 billion

Approximately $1.80 billion

Capital expenditures

Approximately $550 million

Approximately $550 million

Note on Non-GAAP Financial Measures

As used in this press release the term "reported" refers to measures under accounting principles generally accepted in the United States ("GAAP"). The term "adjusted" refers to non-GAAP operating performance measures that exclude special items such as restructuring and integration charges, amortization expense, excess tax benefits ("ETB") associated with stock-based compensation, gains and losses associated with changes in the carrying value of our strategic investments and other items.

Non-GAAP adjusted measures are presented because management believes those measures are useful adjuncts to GAAP results. Non-GAAP adjusted measures should not be considered as an alternative to the corresponding measures determined under GAAP. Management may use these non-GAAP measures to evaluate our performance period over period and relative to competitors, to analyze the underlying trends in our business, to establish operational budgets and forecasts and for incentive compensation purposes. We believe that these non-GAAP measures are useful to investors and analysts to evaluate our performance period over period and relative to competitors, as well as to analyze the underlying trends in our business and to assess our performance. The additional tables attached below include reconciliations of non-GAAP adjusted measures to GAAP measures.

Conference Call Information

Quest Diagnostics will hold its quarterly conference call to discuss financial results beginning at 8:30 a.m. Eastern Time today. The conference call can be accessed by dialing 888-455-0391 within the U.S. and Canada, or 773-756-0467 internationally, passcode: 7895081; or via live webcast on our website at www.QuestDiagnostics.com/investor. We suggest participants dial in approximately 10 minutes before the call.

A replay of the call may be accessed online at www.QuestDiagnostics.com/investor or, from approximately 10:30 a.m. Eastern Time on October 22, 2026 until midnight Eastern Time on November 5, 2026, by phone at 866-388-5361 for domestic callers or 203-369-0416 for international callers. Anyone listening to the call is encouraged to read our periodic reports, on file with the Securities and Exchange Commission, including the discussion of risk factors and historical results of operations and financial condition in those reports.

(Press release, Quest Diagnostics, OCT 22, 2026, View Source [SID1234673673])

On October 22, 2026 Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Moderna, Inc. (NASDAQ: MRNA) reported detailed positive recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) results from the Phase 3 INTerpath-001 trial evaluating intismeran autogene (intismeran; V940 or mRNA-4157), a novel investigational mRNA-based individualized neoantigen therapy (INT) being jointly developed by Merck and Moderna, in combination with KEYTRUDA (pembrolizumab), Merck’s anti-PD-1 therapy, as adjuvant treatment for patients with completely resected stage IIB-IV melanoma. These late-breaking results will be presented for the first time during Presidential Symposium I at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress 2026 (Presentation #LBA1), were selected for an official ESMO (Free ESMO Whitepaper) Press Briefing and have been accepted for publication in The New England Journal of Medicine.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

At the primary pre-specified analysis (intention-to-treat), after a median follow-up of 24.6 months, intismeran in combination with KEYTRUDA significantly reduced the risk of recurrence or death by 42% (HR=0.58 [95% CI, 0.45–0.75]; two-sided p<0.001). Intismeran plus KEYTRUDA also significantly reduced the risk of distant metastasis or death by 38% (HR=0.62 [95% CI, 0.45–0.85]; two-sided p=0.002) compared to KEYTRUDA alone. The improvements observed in RFS and DMFS were generally consistent across pre-specified patient subgroups. Overall survival (OS) data are not yet mature, but a favorable trend in OS with intismeran plus KEYTRUDA has been observed. The study remains ongoing to further evaluate OS and other key endpoints. The safety profile of intismeran plus KEYTRUDA was generally consistent with previously reported studies of the combination, and no new safety signals were observed. Based on these data, we are engaging with regulatory authorities.

The efficacy of the intismeran immunization plus KEYTRUDA in the first six months was comparable with KEYTRUDA alone for risk of recurrence or death (HR=0.99 [95% CI, 0.66–1.49]) and risk of distant metastasis or death (HR=1.01 [95% CI, 0.58–1.79]). At six months, following the intismeran immunization regimen, a pre-specified sensitivity analysis of the primary endpoint showed the addition of intismeran plus KEYTRUDA reduced the risk of recurrence or death by 58% (HR=0.42 [95% CI, 0.30–0.58]) and reduced the risk of distant metastasis or death by half (HR=0.50 [95% CI, 0.34–0.73]) compared to KEYTRUDA alone.

In a pre-specified sensitivity analysis of the modified intent-to-treat (mITT) population, which excluded participants who did not receive at least one dose of intismeran or placebo as planned, intismeran plus KEYTRUDA reduced the risk of recurrence or death by 49% (HR=0.51 [95% CI, 0.39–0.67]) and the risk of distant metastasis or death by 45% (HR=0.55 [95% CI, 0.40–0.77]) compared to KEYTRUDA alone.

"The transformative INTerpath-001 results have the potential to make a foundational shift in how we treat patients with earlier-stage melanoma in the adjuvant setting," said Professor Georgina Long, the study’s principal investigator and medical director of Melanoma Institute Australia, Chair of Melanoma Medical Oncology and Translational Research at the University of Sydney. "For decades, cancer treatment has largely been defined by where a tumor originates in the body. The INTerpath-001 findings support a fundamentally new and individualized approach to treating resected melanoma in the adjuvant setting, one that tailors treatment to the unique mutational signature of a patient’s tumor to enhance an anti-tumor immune response. While these results are in patients with completely resected stage IIB-IV melanoma, they provide valuable insights and will help inform our understanding of intismeran as clinical research continues into other tumor types and across settings."

"INTerpath-001 is the first Phase 3 study to demonstrate a clinically meaningful improvement in RFS and DMFS over standard-of-care KEYTRUDA in patients with resected melanoma, setting a new benchmark in the adjuvant setting and representing one of the most significant advances in melanoma treatment since the advent of immunotherapy," said Dr. Dean Y. Li, president, Merck Research Laboratories. "These results, building on the body of evidence from the Phase 2b study, strengthen our confidence in the curative potential of intismeran autogene when given in combination with KEYTRUDA. Importantly, these data suggest that, by intervening earlier, this approach may offer a tangible opportunity to change the trajectory of a patient’s cancer."

"From the beginning, we believed mRNA technology could make it possible to develop cancer treatments uniquely matched to each patient’s tumor. The INTerpath-001 results mark a defining moment for that vision and show what’s possible when we rethink how medicines are made," said Stéphane Bancel, Chief Executive Officer of Moderna. "These results reinforce our conviction that mRNA has the potential to fundamentally change how we treat cancer."

Merck and Moderna are advancing the robust INTerpath clinical development program evaluating the safety and efficacy of intismeran in combination with KEYTRUDA and other anti-cancer therapies, and as a monotherapy. The INTerpath program currently consists of nine total Phase 2 and Phase 3 clinical trials across multiple tumor types and stages of disease, including three ongoing Phase 3 trials in non-small cell lung cancer (NSCLC). Additional clinical studies include the Phase 2b KEYNOTE-942/mRNA-4157-P201 trial in adjuvant melanoma and a Phase 1 study exploring adjuvant pancreatic ductal adenocarcinoma (Abstract #3151P), perioperative gastric carcinoma and perioperative NSCLC.

The results from INTerpath-001 build on previously reported Phase 2b results for intismeran in combination with KEYTRUDA from the KEYNOTE-942/mRNA-4157-P201 trial, including the five-year follow-up data presented at the 2026 ASCO (Free ASCO Whitepaper) Annual Meeting.

Study design and additional data from INTerpath-001

INTerpath-001 is a randomized, double-blind, placebo- and active-comparator-controlled global Phase 3 trial (ClinicalTrials.gov, NCT05933577) evaluating the safety and efficacy of intismeran in combination with KEYTRUDA compared to KEYTRUDA alone in patients with high-risk (stage IIB-IV) resected cutaneous melanoma. The trial enrolled 1,137 patients who, following complete surgical resection, were randomized 2:1 to receive intismeran (1 mg every three weeks for up to nine doses) and KEYTRUDA (400 mg every six weeks up to nine cycles [for approximately one year]) compared to placebo plus KEYTRUDA for approximately one year until disease recurrence or unacceptable toxicity, or for a total treatment duration of up to approximately 56 weeks, whichever was sooner.

The primary endpoint is RFS, defined as the time from randomization to any disease recurrence (local, locoregional, regional or distant) as assessed by the investigator, or death due to any cause. Key secondary endpoints include DMFS, OS, safety, tolerability and quality of life.

In the ITT population, the two-year RFS rate was 82.2% (95% CI, 79.3%–84.8%) for intismeran plus KEYTRUDA compared to 70.0% (95% CI, 65.0%–74.5%) for KEYTRUDA alone. Median RFS was not reached (NR) (95% CI, not estimable [NE]–NE) for either arm. Additionally, the two-year DMFS rate was 88.5% (95% CI, 86.0%–90.6%) for intismeran plus KEYTRUDA compared to 80.2% (95% CI, 75.6%–84.0%) for KEYTRUDA alone. Median DMFS was NR (95% CI, NE–NE) for either arm.

Treatment-related adverse events (TRAEs) occurred in 95.8% (723 of 755 patients) receiving intismeran plus KEYTRUDA and 90.0% (342 of 380 patients) receiving KEYTRUDA alone. Grade 3–5 TRAEs occurred in 14.2% (n=107) versus 13.4% (n=51) of patients, respectively. The most common adverse events in the intismeran plus KEYTRUDA arm were pyrexia (52.2%), injection site pain (51.0%) and fatigue (38.5%).

About intismeran autogene

Intismeran autogene (intismeran; V940 or mRNA-4157) is a novel, potential first-in-class investigational messenger RNA (mRNA)-based individualized neoantigen therapy (INT) jointly developed by Merck and Moderna. Intismeran is designed and produced using a patient’s tumor sample to identify the unique mutational signature of their cancer and generate an anti-tumor immune response. Information derived from the patient’s tumor and normal DNA is used to create an individualized treatment design, or "blueprint," informed by selected neoantigens unique to that patient’s cancer. Each therapy consists of a synthetic mRNA coding for up to 34 neoantigens. Upon administration, the RNA-encoded neoantigen sequences are translated in the body and presented to the immune system, a key step in generating specific T-cell responses against cancer cells. Individualized neoantigen therapies are designed to train and activate an anti-tumor immune response based on the unique mutational signature of a patient’s tumor.

About melanoma

Melanoma, one of the deadliest forms of skin cancer, is characterized by the uncontrolled growth of pigment-producing cells. The rates of melanoma have been rising over the past few decades, with more than 338,000 new cases diagnosed worldwide in 2024. In the U.S., skin cancer is one of the most common types of cancer diagnosed, and melanoma accounts for a large majority of skin cancer deaths. It is estimated there will be about 112,000 new cases of melanoma diagnosed and over 8,500 deaths resulting from the disease in the U.S. in 2026 alone. Despite advances in treatment, patients with resected melanoma remain at risk of disease recurrence, which most often occurs within the first two years following surgery. Disease recurrence can be metastatic as well as localized, with more than half of patients who experience recurrence developing one or more distant metastases. Distant metastases can spread to critical organs, including the lung, liver and brain, and are associated with substantially worse outcomes, underscoring the continued need for treatment approaches that can help reduce the risk of recurrence and the risk of local and distant metastasis.

(Press release, Merck & Co, OCT 22, 2026, View Source [SID1234673672])

On October 22, 2026 Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, reported its sales for the year-to-date and third quarter of 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

YTD
2026 YTD
2025 %
change Q3
2026 Q3
2025 %
change
€m €m Actual CER €m €m Actual CER
Oncology 2,196.9 1,912.0 14.9% 16.3% 745.4 624.0 19.4% 17.7%
Rare Disease 498.2 255.4 95.0% 100.1% 193.5 102.0 89.6% 88.6%
Neuroscience 669.1 567.3 17.9% 18.8% 235.1 188.9 24.4% 23.1%
Total Sales 3,364.2 2,734.8 23.0% 24.6% 1,173.9 915.0 28.3% 26.7%
"Our outstanding performance in the first nine months of 2026 is driven by the strength of our core portfolio and continued growth of Somatuline. This momentum, combined with disciplined execution, supports our further upgraded sales and margin guidance for the year," said David Loew, Chief Executive Officer, Ipsen. "Looking ahead, we are excited by the significant opportunities emerging from our pipeline. We have the potential to address substantial unmet needs and expand our reach to new patient populations through Dysport in episodic and chronic migraine and, through Iqirvo with a potential label update in primary biliary cholangitis. We also look forward to the Phase III readout of navtemadlin in myelofibrosis next year. Together with potravitug in post-transplant nephropathy, these differentiated late-stage assets underscore our ambition to bring forward new medicines with blockbuster potential and make a meaningful difference for patients."

Full-year 2026 guidance
Based on the strong year-to-date performance, Ipsen further upgrades its financial guidance for 2026:

Total sales growth around 23.0%, at CER. Based on the current average level of exchange rates in October, an adverse effect from currencies of around 0.5% on total sales is expected
Core operating margin around 39.0% of total sales
Full-year guidance on total sales and core operating margin assumes strong double-digit sales growth of the core portfolio and the growth of Somatuline sales despite the assumed entry of generic lanreotide in the fourth quarter.

External innovation
During the third quarter, Ipsen completed the acquisitions of Memo Therapeutics and Kartos Therapeutics, adding potravitug, a late-stage anti-BK polyomavirus monoclonal antibody, and navtemadlin, a Phase III MDM2 inhibitor for myelofibrosis. These transactions further strengthen Ipsen’s Rare Disease and Oncology pipelines and support the Group’s strategy of building long-term growth through differentiated late-stage assets.

Pipeline update
Ipsen strengthened its late-stage pipeline, advancing key programs and expanding into new disease areas:

In Oncology, the acquisition of navtemadlin, alongside IPN60340, expanded Ipsen’s late-stage presence in hematology across myelofibrosis and acute myeloid leukemia
In Rare Disease, elafibranor continues Phase III development in primary sclerosing cholangitis and regulatory filings for Iqirvo in primary biliary cholangitis are underway, while the recently acquired potravitug adds a Phase II/III program in post-transplant nephropathy
In Neuroscience, regulatory submissions are underway for Dysport as a first botulinum toxin to achieve positive topline Phase III results in chronic and episodic migraine, while corabotase first-in-class recombinant neuroinhibitor (RNITM) progresses through Phase II and Phase III development across therapeutic and aesthetic indications
Galderma arbitration
In October 2026, Galderma initiated two further arbitration proceedings before the International Court of Arbitration of the International Chamber of Commerce (ICC) and the American Arbitration Association (AAA) concerning Ipsen’s new proprietary recombinant neuroinhibitor corabotase. Ipsen disagrees with Galderma’s position regarding the distribution agreements entered into between the Parties since 2007 and intends to vigorously defend its position in both proceedings. In separate proceedings, an ICC Arbitral Tribunal issued a final ruling in January 2026 in favor of Ipsen, dismissing Galderma’s claim related to Ipsen’s alleged wrongful termination of the R&D agreement entered into in 2014; as a result, Ipsen regained full rights to its clinical stage programs in the aesthetic field. Ipsen cannot at this stage reasonably predict the outcome of the proceedings or any potential financial impact.

Conference call
A conference call and webcast for investors and analysts will begin today at 1pm CEST. Participants can access the webcast here. Analysts can join the call and ask questions by registering here.

Calendar
Ipsen intends to publish its full-year results and fourth-quarter sales on 11 February 2027.

Notes
All financial figures are in € millions (€m). The performance shown in this announcement covers the nine-month period to 30 September 2026 (YTD 2026) and the three-month period to 30 September 2026 (Q3 2026), compared to the nine-month period to 30 September 2025 (YTD 2025) and the three-month period to 30 September 2025 (Q3 2025), respectively, unless stated otherwise. Commentary is based on the performance in YTD 2026, unless stated otherwise.

(Press release, Ipsen, OCT 22, 2026, View Source [SID1234673671])

On October 22, 2026 Grid Therapeutics, a clinical-stage biotechnology company committed to developing better and safer human-derived therapeutic antibodies for cancer, reported that new data on its lead clinical asset, GT103, will be presented at the 2026 European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress meeting.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

At the meeting, held October 23–27 in Madrid, Spain, the COMPACT consortium (EP PerMed) will present independent data showing that GT103’s tumor target, complement factor H (CFH), is a novel relevant tumor target in head and neck cancer, and that ex vivo GT103 reduces tumor cell proliferation while increasing tumor T-cells. This will be presented by Dr. Joey Martin (Centre de Recherche des Cordeliers/ Institut Curie, Paris, France).

Poster presentation title: Tumor-bound Factor H controls complement activation and is a potential therapeutic target in oral cavity and HPV-negative oropharyngeal squamous cell carcinoma (ESMO 2026; 1635eP).

GT103 is a tumor specific antibody that has been shown to kill tumor cells, inhibit metastasis, reduce the immunosuppressive environment, and drive anti-tumor immunity. "As we continue to explore and analyze pre-clinical data in different cancer cell types, the clinical development pathway options expand to multiple solid tumors," said Dr. Edward Patz, CEO of Grid. "In addition, we now have the confidence to move forward with additional assets from our computationally driven platform."

(Press release, Grid Therapeutics, OCT 22, 2026, View Source [SID1234673670])

On October 22, 2026 EORTC reported it will showcase a strong portfolio of oral and poster presentations at the ESMO (Free ESMO Whitepaper) Congress 2026, taking place in Madrid, Spain, from 23-27 October 2026. Oral presentations will feature results from clinical and translational research studies, while a broad poster programme will highlight ongoing and planned trials, methodological research, patient involvement initiatives, and quality of life research, reflecting the breadth of EORTC’s multidisciplinary cancer research programme.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

EORTC ABSTRACTS
ORAL PRESENTATIONS
INFORMED CONSENT MATERIALS THROUGH THE EYES OF PATIENTS: A QUALITATIVE ANALYSIS OF EORTC PATIENT REVIEWS
Iryna Shakhnenko, Belgium Saturday, 24 October 2026, 15:47 – 15:52
Type: Rapid Oral Session
Location: Seville Auditorium – NCC
Abstract number: 3324RO
COMPARABLE SWALLOWING FUNCTION AT 12 MONTHS BUT DIVERGENT TOXICITY PROFILES WITH TOS VERSUS DO-IMRT IN EARLY-STAGE OROPHARYNGEAL, SUPRAGLOTTIC AND HYPOPHARYNGEAL CARCINOMA: PRIMARY RESULTS OF THE PHASE III EORTC 1420 BEST-OF TRIAL
Christian Simon, Switzerland Sunday, 25 October 2026, 09:28 – 09:38
Type: Proffered Paper Session
Location: Madrid Auditorium – Hall 4
Abstract number: 1535O
FINAL ANALYSIS OF ADJUVANT PEMBROLIZUMAB (PEMBRO) IN RESECTED EARLY-STAGE NON-SMALL-CELL LUNG CANCER (NSCLC): PHASE 3 PEARLS/KEYNOTE-091 STUDY
Mary O’Brien, United Kingdom Monday, 26 October 2026, 15:43 – 15:53
Type: Proffered Paper Session
Location: Alicante Auditorium – Hall 6
Abstract number: 2511O
POSTERS
IMPACT OF ENZALUTAMIDE-RELATED DRUG–DRUG INTERACTIONS ON ADVERSE EVENTS IN THE EORTC 1333GUCG PEACE-3 TRIAL
Mehdi Bsilat, Belgium Friday, 23 October 2026, 15:15 – 16:00
Type: Poster Session
Location: Lorem ipsum
Abstract number: 2245P
ADJUVANT TEBENTAFUSP (IMCGP100) VERSUS OBSERVATION IN HLA-A*02:01 POSITIVE PATIENTS FOLLOWING DEFINITIVE TREATMENT OF HIGH-RISK UVEAL MELANOMA: AN EORTC RANDOMIZED PHASE III STUDY
Paul Nathan, United Kingdom Saturday, 24 October 2026, 12:00 – 12:45
Type: Trial in Progress Poster
Location: Lorem ipsum
Abstract number: 2139TiP
≥4 POSITIVE NODES IDENTIFY A POPULATION ENRICHED FOR ctDNA-GUIDED ADJUVANT TREATMENT ESCALATION IN ER+/HER2− EARLY BREAST CANCER
Teck Long King, Belgium Saturday, 24 October 2026, 12:00 – 12:45
Type: Poster Session
Location: Lorem ipsum
Abstract number: 583P
ANALYSIS AND REPORTING OF PFS IN CONTEMPORARY PHASE 2-3 TRIALS IN SOLID ONCOLOGY: A SYSTEMATIC REVIEW
Annemiek Van Ommen-Nijhof, Netherlands Sunday, 25 October 2026, 12:00 – 12:45
Type: Poster Session
Location: Lorem ipsum
Abstract number: 3332P
CURRENT PRACTICE CONSIDERATIONS FOR BRAIN METASTASES IN GASTROESOPHAGEAL CANCER PATIENTS: AN INTERNATIONAL EORTC SURVEY
Hannah C. Puhr, Austria Lorem ipsum
Type: E-Poster
Location: Lorem ipsum
Abstract number: 749eP
COVERAGE OF TREATMENT-RELATED TOXICITIES BY EORTC QLQ-C30 AND QLQ-H&N43 IN HEAD AND NECK CANCER
Myrto Moutafi, Greece Lorem ipsum
Type: E-Poster
Location: Lorem ipsum
Abstract number: 1622eP
DIAGNOSIS, TREATMENT AND FOLLOW-UP PRACTICES FOR LOCALLY ADVANCED NASOPHARYNGEAL CANCER (NPC) IN NON-ENDEMIC REGIONS: AN EORTC LED SURVEY
Alvina Vadassery, Belgium Lorem ipsum
Type: E-Poster
Location: Lorem ipsum
Abstract number: 1623eP

(Press release, EORTC, OCT 22, 2026, View Source [SID1234673669])